Morgan Stanley Cybin Inc. Transaction History

Morgan Stanley

$1.27 Trillion
Q2 2024

A detailed history of Morgan Stanley transactions in Cybin Inc. stock. As of the latest transaction made, Morgan Stanley holds 106,404 shares of CYBN stock, worth $940,611. This represents 0.0% of its overall portfolio holdings.

Number of Shares

106,404

Previous 61,618 72.68%

Holding current value

$940,611

Previous $25,000 12.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.26 - $0.46 $11,644 - $20,601	44,786 Added 72.68%	106,404 $28,000
Q1 2024 Aug 16, 2024	BUY	$0.3 - $0.46 $4 - $6	14 Added 0.02%	61,618 $25,000
Q1 2024 May 15, 2024	BUY	$0.3 - $0.46 $4 - $6	14 Added 0.02%	61,618 $25,000
Q4 2023 Aug 16, 2024	SELL	$0.38 - $0.65 $17,024 - $29,120	-44,800 Reduced 42.1%	61,604 $25,000
Q4 2023 Feb 13, 2024	BUY	$0.38 - $0.65 $1,520 - $2,600	4,000 Added 6.94%	61,604 $25,000
Q2 2023 Aug 14, 2023	SELL	$0.23 - $0.39 $598,000 - $1.01 Million	-2,600,000 Reduced 97.83%	57,604 $21,000
Q1 2023 May 15, 2023	BUY	$0.3 - $0.56 $13,250 - $24,734	44,169 Added 1.69%	2,657,604 $1.01 Million
Q4 2022 Feb 14, 2023	SELL	$0.26 - $0.64 $4,759 - $11,714	-18,304 Reduced 0.7%	2,613,435 $784,000
Q3 2022 Nov 14, 2022	BUY	$0.48 - $1.11 $1.26 Million - $2.91 Million	2,620,404 Added 23117.81%	2,631,739 $1.27 Million
Q1 2022 May 13, 2022	BUY	$0.74 - $1.22 $1,480 - $2,440	2,000 Added 21.42%	11,335 $9,000
Q4 2021 Feb 14, 2022	BUY	$1.13 - $2.31 $2,373 - $4,851	2,100 Added 29.03%	9,335 $11,000
Q3 2021 Nov 15, 2021	BUY	$1.83 - $3.18 $13,240 - $23,007	7,235 New	7,235 $16,000

Others Institutions Holding CYBN

# of Institutions

102

Shares Held

270M

Call Options Held

Put Options Held

View Full List

About CYBIN INC.

Ticker CYBN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 166,120,000
Market Cap $1.47B
Description
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...

More about CYBN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account